3 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMOCompleted
The aim of the study is to assess the risk of impaired driving in the morning at 3 and 4 hours after a middle-of-the-night dose of zolpidem tartrate sublingual tablet 3.5 mg.
Approved WMORecruiting
The objective of the proposed study is to assess the effectiveness and cost-effectiveness of the use of oil versus water-based contrast medium in terms of live birth in women undergoing HSG, who:1: have ovulation disorders or;2: are at high risk for…